JP7682512B2 - メトトレキサートの眼科用製剤 - Google Patents

メトトレキサートの眼科用製剤 Download PDF

Info

Publication number
JP7682512B2
JP7682512B2 JP2022515885A JP2022515885A JP7682512B2 JP 7682512 B2 JP7682512 B2 JP 7682512B2 JP 2022515885 A JP2022515885 A JP 2022515885A JP 2022515885 A JP2022515885 A JP 2022515885A JP 7682512 B2 JP7682512 B2 JP 7682512B2
Authority
JP
Japan
Prior art keywords
composition
mtx
administered
concentration
methotrexate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022515885A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548226A5 (cg-RX-API-DMAC10.html
JP2022548226A (ja
Inventor
ディーン エリオット，
スティーブン ギツ マチャサ，
プラモッド サルポトダル，
トマシュ ストリエフスキ，
Original Assignee
アルデイラ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルデイラ セラピューティクス， インコーポレイテッド filed Critical アルデイラ セラピューティクス， インコーポレイテッド
Publication of JP2022548226A publication Critical patent/JP2022548226A/ja
Publication of JP2022548226A5 publication Critical patent/JP2022548226A5/ja
Application granted granted Critical
Publication of JP7682512B2 publication Critical patent/JP7682512B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2022515885A 2019-09-13 2020-09-11 メトトレキサートの眼科用製剤 Active JP7682512B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962900060P 2019-09-13 2019-09-13
US62/900,060 2019-09-13
US202063044288P 2020-06-25 2020-06-25
US63/044,288 2020-06-25
PCT/US2020/050565 WO2021051003A1 (en) 2019-09-13 2020-09-11 Ophthalmic formulations of methotrexate

Publications (3)

Publication Number Publication Date
JP2022548226A JP2022548226A (ja) 2022-11-17
JP2022548226A5 JP2022548226A5 (cg-RX-API-DMAC10.html) 2023-09-20
JP7682512B2 true JP7682512B2 (ja) 2025-05-26

Family

ID=74866765

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022515885A Active JP7682512B2 (ja) 2019-09-13 2020-09-11 メトトレキサートの眼科用製剤

Country Status (9)

Country Link
US (4) US12616699B2 (cg-RX-API-DMAC10.html)
EP (1) EP4028015A4 (cg-RX-API-DMAC10.html)
JP (1) JP7682512B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220062617A (cg-RX-API-DMAC10.html)
CN (1) CN114423432A (cg-RX-API-DMAC10.html)
AU (1) AU2020344685A1 (cg-RX-API-DMAC10.html)
CA (1) CA3149467A1 (cg-RX-API-DMAC10.html)
IL (1) IL291228A (cg-RX-API-DMAC10.html)
WO (1) WO2021051003A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
CN111135171B (zh) 2013-01-23 2023-09-08 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
CN112714762A (zh) 2018-08-06 2021-04-27 奥尔德拉医疗公司 多晶型化合物及其用途
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
WO2021051003A1 (en) 2019-09-13 2021-03-18 Aldeyra Therapeutics, Inc. Ophthalmic formulations of methotrexate
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
WO2024129979A1 (en) * 2022-12-14 2024-06-20 Aldeyra Therapeutics, Inc. Methotrexate treatment methods
US11911385B1 (en) 2022-12-14 2024-02-27 Aldeyra Therapeutics, Inc. Methotrexate treatment methods

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540561A (ja) 2005-05-11 2008-11-20 ボーシュ アンド ローム インコーポレイティド 非増殖性糖尿病網膜症の進行を防止しまたはその進行速度を低下させる非外科的方法および眼の他の症状を治療する非外科的方法
JP2012519692A (ja) 2009-03-03 2012-08-30 アルコン リサーチ， リミテッド レセプターチロシンキナーゼ阻害（ＲＴＫｉ）化合物の眼への送達のための薬学的組成物
JP2017523974A (ja) 2014-07-30 2017-08-24 マサチューセッツ アイ アンド イヤー インファーマリー 増殖性硝子体網膜症用メトトレキサート
JP2017533274A (ja) 2014-10-29 2017-11-09 セラカインド リミテッドＴｈｅｒａｋｉｎｄ Ｌｔｄ メトトレキサート製剤
JP2019503352A (ja) 2015-12-18 2019-02-07 ミデタク ファーマ（ウェールズ）リミテッド 徐放性シクロスポリン添加微粒子

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253243A1 (en) 2003-01-21 2004-12-16 David Epstein Aptamer therapeutics useful in ocular pharmacotherapy
US20050255144A1 (en) 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US20050101605A1 (en) 2003-11-07 2005-05-12 Ahmed Salah U. Oral liquid formulations of methotrexate
WO2005046746A2 (en) 2003-11-10 2005-05-26 Angiotech International Ag Medical implants and fibrosis-inducing agents
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
MX2007003968A (es) 2004-10-01 2008-03-04 Ramscor Inc Composiciones de farmaco de liberacion sostenida convenientemente implantables.
CA2597590A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
JP2008539276A (ja) 2005-04-27 2008-11-13 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド ヒト疾患に関連する変異体タンパク質の分解能を改善するための材料及び方法
US20090081277A1 (en) 2007-09-21 2009-03-26 Allergan, Inc. Pharmaceutical formulations and methods for treating ocular conditions
US20110200662A1 (en) 2008-10-22 2011-08-18 Arnold Glazier Method For The Treatment Of Proliferative Disorders Of The Eye
GB201200192D0 (en) * 2012-01-06 2012-02-22 Rosemont Pharmaceuticals Ltd Methotrexate composition
WO2014033184A1 (en) * 2012-08-28 2014-03-06 Novartis Ag Use of a vegf antagonist in treating ocular vascular proliferative diseases
US20140105956A1 (en) 2012-10-11 2014-04-17 Rupak BANERJEE Biodegradable polymer based microimplant for ocular drug delivery
AU2013342275B2 (en) 2012-11-08 2017-11-09 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
WO2018201146A1 (en) 2017-04-28 2018-11-01 Case Western Reserve University Compounds and methods of treating retinal degeneration
CA3092828A1 (en) 2018-03-01 2019-09-06 The Trustees Of Columbia University In The City Of New York Compounds, compositions, and methods for suppressing toxic endoplasmic reticulum stress
WO2021051003A1 (en) 2019-09-13 2021-03-18 Aldeyra Therapeutics, Inc. Ophthalmic formulations of methotrexate
US12678440B2 (en) 2020-02-26 2026-07-14 Case Western Reserve University Compositions and methods for treating misfolded protein ocular disorders
WO2024129979A1 (en) 2022-12-14 2024-06-20 Aldeyra Therapeutics, Inc. Methotrexate treatment methods
US11911385B1 (en) 2022-12-14 2024-02-27 Aldeyra Therapeutics, Inc. Methotrexate treatment methods

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540561A (ja) 2005-05-11 2008-11-20 ボーシュ アンド ローム インコーポレイティド 非増殖性糖尿病網膜症の進行を防止しまたはその進行速度を低下させる非外科的方法および眼の他の症状を治療する非外科的方法
JP2012519692A (ja) 2009-03-03 2012-08-30 アルコン リサーチ， リミテッド レセプターチロシンキナーゼ阻害（ＲＴＫｉ）化合物の眼への送達のための薬学的組成物
JP2017523974A (ja) 2014-07-30 2017-08-24 マサチューセッツ アイ アンド イヤー インファーマリー 増殖性硝子体網膜症用メトトレキサート
JP2017533274A (ja) 2014-10-29 2017-11-09 セラカインド リミテッドＴｈｅｒａｋｉｎｄ Ｌｔｄ メトトレキサート製剤
JP2019503352A (ja) 2015-12-18 2019-02-07 ミデタク ファーマ（ウェールズ）リミテッド 徐放性シクロスポリン添加微粒子

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ama Sadaka, et al.，Intravitreal methotrexate infusion for proliferative vitreoretinopathy，Clinical Ophthalmology，2016年09月19日，Vol.10，1811-1817

Also Published As

Publication number Publication date
WO2021051003A1 (en) 2021-03-18
US20230018197A1 (en) 2023-01-19
US20230017743A1 (en) 2023-01-19
US12616699B2 (en) 2026-05-05
CA3149467A1 (en) 2021-03-18
KR20220062617A (ko) 2022-05-17
US12005060B2 (en) 2024-06-11
US20260224578A1 (en) 2026-08-06
CN114423432A (zh) 2022-04-29
EP4028015A4 (en) 2023-11-15
US20220370460A1 (en) 2022-11-24
US12005061B2 (en) 2024-06-11
EP4028015A1 (en) 2022-07-20
IL291228A (en) 2022-05-01
AU2020344685A1 (en) 2022-04-14
JP2022548226A (ja) 2022-11-17

Similar Documents

Publication Publication Date Title
US12005061B2 (en) Ophthalmic formulations of methotrexate
AU2017200608B2 (en) Liquid pharmaceutical composition for the treatment of a posterior eye disease
US20220184057A1 (en) Combination treatment of ocular inflammatory disorders and diseases
CN112135603B (zh) 包含奈必洛尔的药物组合物
JP7496778B2 (ja) チモロールを含む医薬組成物
KR20080059280A (ko) 녹내장의 원발성 및 ２차 형태의 치료 방법
EP3174540B9 (en) Methotrexate for proliferative vitreoretinopathy
JP2022116147A (ja) 一酸化窒素放出プロスタミドを含有する眼科用組成物
TWI705812B (zh) 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
GR1009419B (el) Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου
Mautino et al. Case studies on adverse effects of drugs used in ocular treatment
WO2025090106A1 (en) Compositions and methods for treating neural degeneration in glaucoma and related conditions
HK40006489A (en) Liquid pharmaceutical composition for the treatment of a posterior eye disease
Escott et al. Medical Management of CME Associated with Uveitis
HK1235304B (en) Liquid pharmaceutical composition for the treatment of a posterior eye disease
HK1235304A1 (en) Liquid pharmaceutical composition for the treatment of a posterior eye disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230911

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230911

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250401

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250424

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250506

R150 Certificate of patent or registration of utility model

Ref document number: 7682512

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150